

# Cardiac Electrophysiology for the USMLE Step One Exam



## Cardiology Overview Patients

Matthew McGuiness, MD, MEd



*Howard J. Sachs, MD*

*Associate Professor of Medicine*

*University of Massachusetts Medical School*

*[www.12DaysinMarch.com](http://www.12DaysinMarch.com); Season III*

*[E-mail: Howard@12daysinmarch.com](mailto:Howard@12daysinmarch.com)*

# Cardiology Overview

## *Patients*


Matthew McGuiness, MD, MEd

# Outline



- \* Cardiac electro-mechanical function
  - \* Electrophysiology and myocyte function
  - \* Pump function and hemodynamics
- \* Cardiac rhythm disturbances and antiarrhythmic drugs

# Two Major Elements of Pump Function


- \* Electrical system
  - \* Generates spontaneous activation
  - \* Rapidly disperses activation wavefront
- \* Mechanical system (myocytes)



# Cardiac Action Potential




# Cardiac Action Potential




# Putting it together...

## Intrinsic conduction system of the heart




# Myocyte Structure







# Myocyte Contraction



# Myocyte Contraction




(a) Myosin-binding sites blocked




(b) Myosin-binding sites exposed


# Myocyte Contraction



# Myocyte Contraction



# Cardiac Rhythm Disturbances and Antiarrhythmic Drugs






# Context

- \* Complete understanding of rhythm identification is not necessary
- \* Knowledge of rhythm-related pathophysiology and pharmacology will be very useful

# Foundation

- \* (Sinus Node)
- \* **Atrial depolarization = P**
- \* (AV node, His Purkinje, left and right bundles)
- \* **Ventricular depolarization= QRS**
- \* (Atrial repolarization)
- \* **Ventricular repolarization = T**






**PR interval: beginning of atrial depol to beginning of ventricular depol**

**QRS duration: ventricular depolarization**

**QT interval: beginning of ventricular depol to end of ventricular repol**





# Cardiac Arrhythmias



# Bradyarrhythmias

- \* Heart rate is too slow
  - \* Impulse generation (sinus bradycardia)
  - \* Impulse conduction (complete AV block)
- \* Common causes: age-related degeneration, drug effects, hypothyroidism, Lyme disease
- \* Treatment: reverse underlying cause or pacemaker


# Complete Heart Block



# Tachyarrhythmias

- \* Heart rate is too fast
- \* Two main mechanisms
  - \* Automatic arrhythmias
  - \* Re-entrant arrhythmias

# Automatic Tachycardias




- \* Focal area within the heart depolarizing at a rapid rate
- \* Most common example: sinus tachycardia!
- \* Atrial tachycardia, rare forms of ventricular tachycardia
- \* Common causes of AT: systemic illness, hyperthyroidism, lung disease, atrial dilation
- \* Treatment:  $\beta$  or  $\text{Ca}^{++}$  blockers, ablation

# Re-entry



- \* Complicated but important concept
- \* Underlies how many arrhythmias are treated, including the use of antiarrhythmic drugs
- \* Re-entrant arrhythmias also called circus movement tachycardias


# Re-entry




- \* Common entry point
- \* Two potential pathways with different:
  - \* Conduction speeds
  - \* Refractory periods
- \* Common exit point
  
- \* This loop can exist in many locations within the heart.

# Re-entry

Baseline



Tachycardia





# Examples of Re-entry Rhythms

- \* Wolf-Parkinson-White tachycardia
- \* AV nodal re-entrant tachycardia
- \* Atrial flutter
- \* Ventricular tachycardia (most common forms)
- \* Pacemaker-mediated tachycardia
- \* Atrial fibrillation (certain aspects)

# Treatment of Re-entry Rhythms

- \* Antiarrhythmic drugs work by changing the electrical properties of the re-entry loop, so that circular electrical activity can no longer be sustained
- \* Ablation can physically destroy part of the re-entry loop.

# Anti-arrhythmic Drugs

- \* True AADs alter the myocyte action potential by blocking  $\text{Na}^+$  or  $\text{K}^+$  channels
- \* Though drug mechanisms often described ‘purely,’ many drugs interact with multiple receptors
- \* AADs can actually cause arrhythmias!
  - \* Drugs that have  $\text{K}^+$  channel activity will prolong repolarization (QT interval) and may lead to TdP
  - \* “Bystander” re-entry loops, usually in the LV, may become malignant


# Vaughan Williams Classifications

- \* Class I – Na<sup>+</sup> channel blockers
- \* Class II – β blockers
- \* Class III – K<sup>+</sup> channel blockers
- \* Class IV – Ca<sup>++</sup> blockers
- \* Class V – misc

# Antiarrhythmic drugs worth knowing – for boards and career!



# Action Potential Effects (Class I)




K<sup>+</sup>

Class III

$\Delta$  QT interval

Delayed Repolarization by Potassium-Channel Blockade



Ventricular Action Potential

## Antiarrhythmics: Class I (Na)

P

1a. Procainamide

r

o

L

1b. Lidocaine

i

F

i

1c. Flecainide

c

# Antiarrhythmics: Class I (Na)

Phase 0 Inhibition

AP Duration

P

1a. Procainamide  
Old

Intermed

Prolongs

r

o

L

1b. Lidocaine  
MI

Weak

Shortens

F

i

c

1c. Flecainide  
New

Strong

No  $\Delta$



# Antiarrhythmics: Class I (Na)


Phase 0 Inhibition

AP Duration

P  
r  
o  
l  
i  
f  
i  
c

1a. Procainamide  
Old


Intermed



Prolongs

1b. Lidocaine  
MI


Weak



Shortens

1c. Flecainide  
New

Strong





No  $\Delta$

## Antiarrhythmics: Class

P  
r  
o  
L  
i

1b. Lidocaine  
Mexilitine

- Slight Phase 0 inhibition
- AP duration – no  $\Delta$
- **Fast on/fast off**
- Safe peri-infarction



## Antiarrhythmics: Class I (Na)

P

r

o

L

i

F

i

C

1a. **P**rocainamide  
Quinidine  
Disopyramide



1c. **F**lecainide  
Propafenone




# Antiarrhythmics: Class I (Na)

P  
r  
o  
l  
i  
f  
i  
c

Na Channel Effect  
(Phase 0 depolarization)


1a. Procainamide  
Quinidine  
Disopyramide

Modest



1c. Flecainide  
Propafenone

Strong




# Antiarrhythmics: Class I (Na)

P  
r  
o  
l  
i  
f  
i  
c




AP duration

1a. **P**rocaïnamide  
Quinidine  
Disopyramide



Prolonged


1c. **F**lecainide  
Propafanone



$\Phi$

## Antiarrhythmics: Class I (Na)

1c. **Flecainide**  
Propafenone



P  
r  
o  
L



### 'Use Dependence'

- Slowly dissociates from Na channel **during diastole**.
- At faster HR (less diastole), less time to dissociate, with enhanced Na channel blocking effects.
- **QRS widens**, but AP duration remains the same

P  
r  
o  
L  
i  
F  
i  
c



1a. Procainamide

Modest




1b. Lidocaine

$\Phi$



1c. Flecainide

$\Phi$



P

r

o

L

i

F

i

C

1a. Procainamide



Anti-histone Aby


Slow acetylators



# Procainamide




- \* Class 1A agent
- \* Metabolized to NAPA, with longer half life
- \* Modestly effective, modestly pro-arrhythmic
- \* Associated with drug-induced lupus and anti-histone ab production
- \* Limited contemporary clinical use




# Lidocaine & Mexilitine

- \* Class 1B agents
- \* Safe and effective for ventricular dysrhythmias, including in the context of myocardial ischemia
- \* Limited contemporary clinical use




# Flecainide & Propafenone

- \* Class 1 C agents
- \* Predominantly used for atrial fibrillation
- \* Demonstrates phenomenon of “use dependence”
  - \* Dissociation from Na channels is time-dependent
  - \* Therefore, less dissociation at higher heart rates
  - \* With tachycardia, may see more pronounced drug effects (i.e., QRS widening)






# Sotalol & Dofetilide

- \* Class III – sotalol also with significant beta blocking effects
- \* Effective for atrial (dofetilide) and atrial and ventricular dysrhythmias (sotalol)
- \* Demonstrates “reverse use dependence”
  - \* Easier to remember that QT prolongation is expected, and will be more pronounced at slower heart rates
- \* Renal clearance



# Amiodarone

- \* Class III, but multiple mechanisms of action
- \* Remarkably effective drug for many dysrhythmias
- \* Prolongs QT interval, but low incidence of TdP
- \* Multiple potential toxicities, especially with higher cumulative doses




# Adenosine

- \* Miscellaneous agent
- \* Activates A1 receptor in heart, causing transient (seconds) complete AV block
- \* MoA: excessive  $K^+$  efflux in the AVN  $\rightarrow$  cell hyperpolarization (but  $Na^+$  and  $Ca^+$  currents likely also involved)
- \* Also has vasodilatory properties, especially in coronary circulation
- \* How might such action be useful clinically?

# Adenosine

- \* Therapeutically
- \* Diagnostically





# Summary

- \* Arrhythmias can be categorized as slow or fast
- \* Tachycardias may have an automatic or re-entry mechanism
- \* Principle of re-entry underlies the pathogenesis and treatment of many dysrhythmias
- \* Antiarrhythmic drugs can be safe and effective, but carry risks, and must be used cautiously

# Cardiac Electrophysiology for the USMLE Step One Exam



## Cardiology Overview Patients

Matthew McGuiness, MD, MEd



*Howard J. Sachs, MD*

*Associate Professor of Medicine*

*University of Massachusetts Medical School*

*[www.12DaysinMarch.com](http://www.12DaysinMarch.com); Season III*

*[E-mail: Howard@12daysinmarch.com](mailto:Howard@12daysinmarch.com)*